Breast cancer care is entering a new phase, with AI helping doctors estimate recurrence risk, spot disease earlier, and shape radiation treatment around each patient’s anatomy. Two developments reported in October 2026 show how the technology is moving from image analysis into decisions that can influence the full treatment journey.
One development focuses on what may happen after diagnosis. The other focuses on treating the area where cancer was removed while protecting healthy tissue. Together, they point toward a more tailored approach to breast cancer care.
An AI Tool Turns Breast MRI Into a Recurrence Risk Score
SimBioSys announced on October 15, 2026, that the U.S. Food and Drug Administration granted 510(k) clearance to TumorSight Risk, an AI software device that analyzes breast MRI scans alongside pathology and clinical data. The tool estimates a patient’s risk of breast cancer recurrence at five and ten years.
SimBioSys, a Chicago-based company, describes TumorSight Risk as the world’s first AI-powered, MRI-derived prognostic tool for assessing breast cancer recurrence risk. The device is intended to serve as a prognostic indicator of recurrence-free survival at five and ten years in adult women with hormone receptor-positive, HER2-negative Stage I–IIIA breast cancer.
That group represents 75 percent of all breast cancers in the United States, giving the software a broad target population. TumorSight Risk produces a score from zero to 100, dividing patients into three risk levels:
- High risk: a score above 35
- Intermediate risk: a score above 20 through 35
- Low risk: a score of 20 or below
The device is cleared for use with GE 1.5T, GE 3T, Siemens 1.5T, and Siemens 3T MRI scanners. The FDA clearance letter is dated September 25, 2026, and the premarket notification was dated and received January 5, 2026.
The FDA determined that TumorSight Risk is substantially equivalent to a legally marketed predicate. It is a Class II prescription device under the FDA regulation covering software algorithm devices that analyze digital images for cancer prognosis.
AI Is Expanding the Breast Cancer Detection Conversation
TumorSight Risk arrives as doctors and researchers examine how AI can support breast cancer screening before and after a diagnosis. Research shows that mammograms paired with AI evaluations can find cancer up to five years earlier, while AI breast cancer screening software can predict future breast cancer risk even when a mammogram detects no cancer.
Dr. Rachel Brem, a board-certified diagnostic radiologist and director of Breast Imaging and Intervention at George Washington University, has used AI in every mammogram at the university for over four years. She also created the Brem Foundation to help prevent breast cancer from taking more lives, championing early detection, education, awareness, and equitable access for 20 years.
“AI is going to change everything in medicine, and certainly breast cancer detection,” Brem said. Yet access remains uneven. Nationwide, only 20% of practices use AI with their mammogram procedures, and AI readings often cost extra, making them less accessible.
The stakes are especially clear across racial groups: Black women die at a 40% higher rate from breast cancer than White women. Brem is also collaborating with ScreenPoint Medical to develop Transpara, an AI breast cancer screening software. The FDA has cleared some AI technology to predict the risk of or detect breast cancer.
Screening recommendations remain part of the debate. Current guidelines from the American College of Physicians in 2026 recommend that women over 50 get a mammogram every other year, while the United States Preventive Services Task Force recommends that women start screening every other year at age 40. Brem advocates for annual screening beginning at age 40, or at 35 if there is a family history.
“You’re not too young to have breast cancer,” Brem said. “If you find it early, even if you’re young, it’s curable.” Early detection leads to significantly better outcomes, with 99% of women with early breast cancer surviving and thriving.
Adaptive Radiation Targets Cancer While Protecting Healthy Tissue
AI is also changing what happens after a tumor is found. Natalie Calderon, a 49-year-old, was diagnosed with stage 1 breast cancer after a vivid dream prompted her to get checked. Following a lumpectomy, she received AI-assisted adaptive radiation therapy through Northwell Health Radiation Medicine.
The treatment targets only the area where cancer was removed, sparing healthy tissue. Adaptive radiation therapy can be tailored and adapted to a patient’s anatomy on the treatment day, creating a more precise treatment plan instead of relying on a fixed target.
Dr. Fleur Gallant, a Northwell Health radiation oncologist involved in the therapy, helped advance an approach that can reduce radiation exposure, scarring, and changes to the breast’s natural appearance. Calderon was sidelined by radiation for only five days and is now cancer free.
Adaptive radiation therapy is also used to target other cancers with greater precision. Its role in breast cancer shows how AI can support treatment as well as detection, helping clinicians focus therapy where it matters most.
Brem is helping develop a breath test that could detect breast cancer without an invasive procedure, but the test remains in experimental and clinical trial phases and is not FDA cleared for screening. For now, she emphasizes that women should advocate for themselves, especially when they have dense breasts.
Women with dense breasts should insist on additional exams such as ultrasounds, MRIs, or contrast-enhanced mammograms. “You absolutely, unequivocally definitely need more exams,” Brem said. “We tell women to be badass.”
The technology is moving fast, but the message is direct: earlier information can open more treatment options, and more precise treatment can protect more healthy tissue. As AI tools gain FDA clearance and adaptive therapy reaches more patients, breast cancer care is becoming more personalized from the first scan through recovery.
Calderon captured that future in her own words: “It could be a chapter in your life, but it’s not your entire story.”
Based on
- SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool — unite.ai
- How technology is changing the detection of breast cancer – CBS News — cbsnews.com
- AI-assisted adaptive radiation therapy acts like a GPS as it targets areas impacted by breast cancer, doctors say – CBS New York — cbsnews.com
